Dr. Alvira Macanovic reports

VENTRIPOINT DIAGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

Ventripoint Diagnostics Ltd. has released its financial results for the second quarter ended June 30, 2023.

Second-quarter highlights

Ventripoint entered into a strategic collaboration with Ascend Cardiovascular, LLC, a leading provider of cardiovascular IT solutions and the two companies have signed a letter of intent to explore joint research and development initiatives, knowledge sharing, and combining efforts to bring innovative AI-based solutions to the market. This collaboration has culminated in the development of a new integrated product with Ascend.

Significant sales to two key centres in Europe, including the largest heart center in Germany, Deutsches Herzzentrum der Charite (DHZC), German Heart Center, in Berlin, Germany and to Medical Center - University of Freiburg im Breisgau, Germany through the efforts of Ventripoint's European Distributor, Angiopro GmbH.

The Company recorded deferred sales for the six months ended June 30, 2023, of $71,986. This will be recorded as revenue when the clients accept the units.

During the three months ended June 30, 2023, the Company recorded a net loss of $1,115,203, compared to net loss of $1,354,578 for the three months ended June 30, 2022. The decrease in net loss was due primarily to an increase in sales and marketing expenses offset by decreases in share-based compensation, professional fees, design costs and external consultants.

During the six months ended June 30, 2023, the Company recorded a net loss of $2,460,538, compared to net loss of $2,363,784 for the for the six months ended June 30, 2022. The increase in net loss was due primarily to an increase in sales and marketing expenses.

During the six months ended June 30, 2023, the Company used cash in operating activities of $1,841,895 compared to cash used in operating activities of $2,005,963 for the for the six months ended June 30, 2022, as the Company ramped up its sales and marketing activities.

Ventripoint President and CEO, Dr. Alvira Macanovic said, "We are making progress on our sales growth plan in our target market segment of congenital heart disorders, and I am pleased with the results we are beginning to realize. We have aggressively pursued many institutions across the United States, United Kingdom, and Europe and are focused on our goal of getting a strong world-wide hold in this market. Looking ahead, we are resolute in achieving our sales growth for 2023 and beyond."

Ventripoint's highest priority for 2023 continues to be to increase awareness that will lead to sales growth and increasing our footprint so that Ventripoint is a well-recognized brand and solution in the cardiology space. Ventripoint continues to reach more cardiovascular centers in the United States, United Kingdom, and Europe through its efforts with its distributors. Ventripoint is completely focused on execution of its strategy, including strategic partnerships.

Ventripoint will host a webinar/conference call at 11:00 a.m. (EST) on Wednesday, September 6, 2023, to discuss its Q2 2023 financial results and to provide an update on sales and marketing activities. Details of the webinar/conference call are as follows:

PARTICIPANT TELEPHONE NUMBERS

Participant Link: https://www.c-meeting.com/web3/joinTo/3WYDHYDEHKKUTR/-Ex5Yhj0J28VjV9fPfIbZw

Alternatively, if participant does not have Internet, please call:

Canada/US Toll Free: 1-844-763-8274

International Toll: +1-647-484-8814

Please dial in 5 - 10 minutes prior to the scheduled start time and simply ask to join the call.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.